Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANZAR: datopotamab deruxtecan + durvalumab + carboplatin versus pembrolizumab + platinum-based chemotherapy in first-line advanced NSCLC
2023-505993-14-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Datopotamab deruxtecan + durvalumab + carboplatin with Pembrolizumab + platinum-based chemotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Jun 2024; status: authorised.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-505993-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505993-14-00.